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Mitochondrial DNA and Traumatic
Brain Injury
Harry Bulstrode, BMBCh,1 James A. R. Nicoll, MD,2 Gavin Hudson, PhD,3
Patrick F. Chinnery, FMedSci,3 Valentina Di Pietro, PhD,4 and
Antonio Belli, MD4,5
Objective: Traumatic brain injury (TBI) is a multifactorial pathology with great interindividual variability in response to
injury and outcome. Mitochondria contain their own DNA (mtDNA) with genomic variants that have different physio-
logical and pathological characteristics, including susceptibility to neurodegeneration. Given the central role of mito-
chondria in the pathophysiology of neurological injury, we hypothesized that its genomic variants may account for
the variability in outcome following TBI.
Methods: We undertook an analysis of mitochondrial haplogroups in a large, well-characterized cohort of 1,094 TBI
patients. A proportional odds model including age, brain computed tomography characteristics, injury severity, pupil-
lary reactivity, mitochondrial haplogroups, and APOE was applied to Glasgow Outcome Score (GOS) data.
Results: mtDNA had a significant association with 6-month GOS (p50.008). Haplogroup K was significantly associ-
ated with favorable outcome (odds ratio51.64, 95% confidence interval5 1.08–2.51, p50.02). There was also a sig-
nificant interaction between mitochondrial genome and age (p5 0.002), with a strong protective effect of both
haplogroups T (p5 0.015) and K (p5 0.017) with advancing age. We also found a strong interaction between APOE
and mitochondrial haplogroups (p50.001), indicating a protective effect of haplogroup K in carriers of the APOE e4
allele.
Interpretation: These findings reveal an interplay between mitochondrial DNA, pathophysiology of TBI, and aging.
Haplogroups K and T, which share a common maternal ancestor, are shown as protective in TBI. The data also sug-
gest that the APOE pathways interact with genetically regulated mitochondrial functions in the response to acute
injury, as previously reported in Alzheimer disease.
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Traumatic brain injury (TBI) is a leading cause ofdeath and disability across all ages and all popula-
tions. Its incidence continues to rise owing to increasing
road use in developing countries and aging in the West-
ern World; by 2020 the World Health Organization pre-
dicts that TBI will represent the third leading cause of
morbidity and mortality worldwide. Understanding the
variability in response to injury between individuals
promises to be key to advances in clinical management.
Existing studies have demonstrated detrimental outcome
associated with the apolipoprotein E e4 allele,1 and there
is evidence for allele-specific differences in outcome for
other genes, including catechol-o-methyltransferase
(COMT), dopamine D2 receptor (DRD2), phosphopro-
tein p53 (TP53), and the calcium channel alpha-1 subu-
nit (CACNA1).2 The mitochondrial genome has received
little attention, despite mitochondria playing a central
role in the pathophysiology of TBI. However, mitochon-
drial DNA (mtDNA) haplogroups have been widely
reported as factors for degenerative pathologies and neu-
rodegenerative conditions, including Parkinson disease
(PD), Alzheimer disease (AD), Huntington disease, and
motor neuron disease.3 For example, in PD, haplogroups
J, T, U, and K, which share a common maternal ancestor
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distinct from the more common haplogroup H, have
been shown by independent studies, and subsequent
meta-analyses, to confer a significant reduction in the
risk of developing the condition.4,5 Associations have also
been identified between mtDNA haplogroups and lon-
gevity; for example, haplogroups K, J, U, and D are
overrepresented in centenarians,6–9 and a recent animal
study by Gilmer et al indicated an age-related increase in
mitochondrial dysfunction following injury.10
The mtDNA encodes factors that are key to the
mechanisms of cell damage and survival after neurological
injury. Therefore, we reasoned that, as reported for neuro-
degenerative disorders, mtDNA haplogroups may account
for some of the individual variability in resilience to TBI.
Patients and Methods
Participants
The study cohort (1,094 patients) was recruited from consecu-
tive TBI admissions to the regional Neurosurgical Unit for the
West of Scotland at the Institute of Neurological Sciences, Glas-
gow between 1996 and 1999. Consent and source DNA (buc-
cal swab or blood sample) were obtained according to local
research ethics committee (REC) permissions as previously
detailed.11 This study originally set out to analyze the effect of
apolipoprotein E (APOE) polymorphism on TBI outcome; the
original consent form allowed for the samples to be retained for
future genetic analysis of novel factors. Subsequent reanalysis of
the existing DNA samples for the purposes of this study was
approved by the Southampton and South West Hampshire
Research Ethics Committee (REC reference 09/H0502/124).
Clinical Features
Patient demographics, mechanism of injury, clinical presenta-
tion, key clinical events (raised intracranial pressure, seizures,
sepsis, systemic complications, and surgery), and radiological
and operative findings were collected prospectively by the study
investigators. The computed tomography (CT) appearances at
presentation were classified according to the Marshall system.12
Outcome
Patients were contacted by mail and telephone at 6 months
after injury. Answers to a structured questionnaire were
obtained by staff unaware of the patient’s status in the acute
stage and of the results of genotyping. Proxy interviews were
utilized wherever the patient was unable to answer the question-
naire in person. The medical records were also reviewed to col-
lect mortality data. The patient’s ability to conduct activities at
home and outside, including shopping, travelling, working, and
leisure activities, and the extent of any family disruption was
used to evaluate their Glasgow Outcome Scale (GOS).13
Some survivors were functioning at a severely disabled
level even prior to injury; these were allocated to the favorable
outcome group if they recovered to their previous state, or to
the unfavorable group if they were left with increased disability
and dependency. Patients for whom the available information
was insufficient to discriminate between moderate disability and
good recovery were allocated to the favorable group if it was
clear that they were independent in society.
mtDNA Haplogrouping
The mtDNA haplogroup was determined from buccal swabs or
blood samples by analysis with polymerase chain reaction and
restriction fragment length polymorphism according to methods
described by Torroni et al.14 By this procedure, each mtDNA
was ascribed to 1 of the 5 haplogroups (H, J, K, T, and U) spe-
cific to European populations. Uncommon haplogroups and
mtDNAs that were not classifiable within a haplogroup were
grouped as “others.”
Exclusions and Missing Data
From the initial study cohort, 91 were determined to have a
chronic subdural hematoma as opposed to an acute head injury
and were therefore excluded, leaving 1,003 eligible patients.
Twenty-two of these were missing follow-up data; additionally,
in 101 patients haplogrouping was not achieved. The 880
remaining patients are analyzed here.
Statistical Analysis
Statistical analysis was undertaken using SPSS software version
20 (IBM Solutions, Armonk, NY).
An ordinal regression analysis (proportional odds model)
was carried out to analyze the effect of mitochondrial hap-
logroups on outcome, in accordance with established statistical
principles in this field.15 The predictors were selected based on
the variables of the “core1CT” model of the International
Mission on Prognosis and Analysis of Clinical trials in Trau-
matic brain injury (IMPACT; http://www.tbi-impact.org).16
These variables include age, motor score of the Glasgow Coma
Scale, pupillary reactivity, hypoxia, hypotension, Marshall CT
classification grade, presence of traumatic subarachnoid hemor-
rhage, and presence of epidural hematoma. This model and its
predictive variables have received external validation in large
cohort studies.17,18 The ordinal regression analysis included the
polychotomous term “mtDNA haplogroup” (H, J, T, U, K,
and others), the dichotomous term “APOE genotype” (e4/non-
e4), and all the above terms, except “epidural hematoma,”
which was not available for our cohort. APOE genotype was
available for every case from the original study.11
For the purpose of the analysis, the 5-point GOS was col-
lapsed into a 4-point scale, pooling together death and vegetative
outcomes. The collapsed GOS scale is commonly used in TBI
studies, as a vegetative outcome is not generally regarded an
improvement from death. The remaining 3 points on this scale
were severe disability, moderate disability, and good outcome.
We also analyzed the interaction between mtDNA hap-
logroups and age, and between mtDNA haplogroup and APOE
by fitting the interaction terms “age by mtDNA haplogroup”
and “APOE genotype by mtDNA haplogroup” into the model.
The ordinal regression analysis assumptions and goodness
of fit were tested and found to be valid. A p value of <0.05
was considered significant.
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TABLE 1. Patient Demographics and Admission Characteristics by Mitochondria Haplogroup Frequency
Followed by Percentage of Total for Given Haplogroup Except Where Stated
Characteristic Haplogroup
H J T U K Other All
Frequency (% of total) 357 (40.5) 122 (13.8) 78 (8.9) 146 (16.6) 74 (8.4) 103 (11.8) 880 (100)
Sex
M 297 96 62 115 65 83 718
F 60 26 16 31 9 20 162
Age, mean yr [SD] 35 [20.7] 38 [24.5] 34 [21.5] 34 [22.5] 34 [20.6] 33 [21.6] 35 [21.7]
Motor score of GCS (%)
No response 30 (8.4) 11 (9) 6 (7.7) 18 (12.3) 4 (5.4) 4 (3.9) 73 (8.3)
Extending to pain 9 (2.5) 2 (1.6) 2 (2.6) 8 (5.5) 4 (5.4) 5 (4.9) 30 (3.4)
Abnormal flexion 10 (2.8) 3 (2.5) 3 (3.8) 1 (0.7) 1 (1.4) 5 (4.9) 23 (2.6)
Withdrawing to pain 33 (9.2) 9 (7.4) 6 (7.7) 12 (8.2) 2 (2.7) 5 (4.9) 67 (7.6)
Localizing to pain 74 (20.7) 23 (18.9) 20 (25.6) 26 (17.8) 18 (24.3) 14 (13.6) 175 (19.9)
Obeying commands 196 (54.9) 70 (57.4) 40 (51.3) 77 (52.7) 43 (58.1) 67 (65) 493 (56)
Not assessable 5 (1.4) 4 (3.3) 1 (1.3) 4 (2.7) 2 (2.7) 3 (2.9) 19 (2.2)
Pupil reactivity (%)
Both 310 (88) 105 (86) 70 (90) 117 (81) 65 (88) 86 (84) 753 (86)
One 18 (5) 4 (3) 3 (4) 13 (9) 5 (7) 7 (7) 50 (6)
Neither 26 (7) 13 (11) 5 (6) 15 (10) 4 (5) 9 (9) 72 (8)
CT grade (%)
N/A 2 (1) 1 (1) 0 1 (1) 1 (1) 0 5 (1)
1 94 (26) 39 (32) 19 (24) 34 (15) 13 (6) 22 (21) 221 (25)
2 132 (37) 44 (36) 31 (40) 58 (40) 38 (51) 38 (37) 341 (39)
3 22 (6) 7 (6) 7 (9) 8 (6) 5 (7) 4 (4) 53 (6)
4 3 (1) 1 (1) 0 0 1 (1) 0 5 (1)
5 84 (24) 22 (18) 17 (22) 37 (25) 11 (15) 36 (17) 207 (24)
6 20 (6) 8 (7) 4 (5) 8 (6) 5 (7) 3 (3) 48 (6)
Traumatic SAH (%)
No 283 (79.3) 99 (81.1) 61 (78.2) 108 (74) 57 (77) 83 (80.6) 691 (78.5)
Yes 74 (20.7) 23 (18.9) 17 (21.8) 38 (26) 17 (23) 20 (19.4) 189 (21.5)
Hypoxia (%) 7 (2) 3 (2.5) 2 (2.6) 1 (3) 0 (0) 5 (2.1) 18 (2)
Hypotension (%) 19 (5.3) 7 (5.7) 7 (9) 10 (6.8) 6 (8.1) 5 (4.9) 54 (6.1)
ApoE (%)
e2 or e3 241 (67.5) 85 (69.7) 50 (64.1) 99 (67.8) 50 (67.6) 63 (61.2) 588 (66.8)
e4 116 (32.5) 37 (30.3) 28 (35.9) 47 (32.2) 24 (32.4) 40 (38.8) 292 (33.2)
CT5 computed tomography; F5 female; GCS5Glasgow Coma Scale; M5male; N/A5 not available; SAH5 subarachnoid
hemorrhage; SD5 standard deviation.
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Results
mtDNA and Response to Injury
The haplogroup distribution was in line with comparable
UK studies,4 with the predominant European haplotype
H accounting for 40.5% of this study population. Mito-
chondrial haplogroup distribution, along with key demo-
graphic and clinical parameters, is shown in Table 1.
The predictive value (R2) of the IMPACT model is
0.35, with the remainder of the variability thought to be
accounted for either genetically or by other biological
factors yet to be identified.19 After adding mitochondrial
haplogroups to the predictive terms of the IMPACT
model, we found a significantly predictive effect of
mtDNA genotype on the 6-month GOS (p5 0.008).
When haplogroups were considered individually,
patients who possessed the K variant had significantly
better outcome than those who did not (odds ratio
[OR]5 1.64, 95% confidence interval [CI]5 1.08–2.51,
p5 0.02). However, individually, there was no significant
association between 6-month outcome and haplogroups
H, J, T, and U, and all other uncommon variants. The
outcome data are shown in Table 2. As expected, all
other predictive terms were found to be significant (Table
3), with the exception of APOE and hypoxia (only 18
patients—2% of the sample—were recorded to have suf-
fered a hypoxic episode).
Interaction between mtDNA and Aging
Mitochondrial dysfunction is a shared feature of TBI and
aging; therefore, we reasoned that mtDNA haplogroups
might differentially modulate the effect of aging as a
determinant of TBI outcome. The inclusion of the inter-
action term “age by haplogroup” in the model revealed a
strong interaction between age and mtDNA haplogroups
(p5 0.002). Possessing either haplogroup K or T
significantly mitigated the negative effect of aging on
outcome (p5 0.017 and p5 0.015, respectively), as
shown by Figure 1A.
These findings are consistent with the evidence
from epidemiological studies showing over-representation
of haplogroup K in longevity and under-representation
of haplogroups K and T in neurodegenerative conditions
such as PD.4,20,21
Interaction between mtDNA and APOE
Genotype
APOE has several known relevant roles after brain injury,
from the maintenance of vascular integrity and function
of the blood–brain barrier to protection against oxidative
stress. APOE has 3 isoforms that have allele-specific
effects (E2>E3>E4) in protecting neuronal cell lines
from oxidative cell death.22 An interaction between
APOE polymorphisms and mtDNA haplogroups in TBI
has been described for AD in a cohort of 213 patients.23
In view of this, we analyzed a possible interaction
between these factors in our cohort. We found this inter-
action to be highly significant (p5 0.001). Specifically,
patients who carried the APOE e4 allele had significantly
better outcome if they also possessed the mtDNA K hap-
logroup (OR5 5.86, 95% CI5 2.14–17.44, p5 0.002),
as shown by Figure 1B.
Discussion
The response to TBI is multifactorial; clinical presenta-
tion, physiological condition, and clinical management
are determinants of outcome, but genetic factors are also
hypothesized to play a key role. Few genomic associations
have been identified in the field of TBI. The APOE gene
is arguably the most extensively studied in this area, and
recently cytokine polymorphisms have also been found to
TABLE 2. Outcomes 6 Months after Head Injury According to Mitochondrial Haplogroup
Parameter GOS Haplogroup
H J T U K Other All
Frequency (% of total) 357 (40.5) 122 (13.8) 78 (8.9) 146 (16.6) 74 (8.4) 103 (11.8) 880 (100)
Outcome (%)
Dead 1 45 (13) 18 (15) 7 (9) 15 (10) 6 (8) 10 (10) 101 (12)
Vegetative 2 13 (4) 4 (3) 2 (3) 7 (5) 2 (3) 5 (5) 33 (4)
Severe disability 3 64 (18) 13 (11) 12 (15) 31 (21) 11 (15) 23 (22) 154 (18)
Moderate disability 4 92 (26) 41 (34) 24 (31) 41 (28) 18 (24) 21 (20) 237 (27)
Good recovery 5 143 (40) 46 (38) 33 (42) 52 (36) 37 (50) 44 (43) 355 (40)
GOS5Glasgow Outcome Scale.
Bulstrode et al.: Mitochondrial DNA and TBI
February 2014 189
TABLE 3. Model Effects
Parameter Category Chi-Square df F OR (95% CI) p
mtDNA haplogroup,
overall effect
15.601 5 3.120 0.008
H 1.57 (0.84–2.96)
J 1.2 (0.55–2.63)
T 1.23 (0.52–2.88)
U 1.14 (0.55–2.39)
K 0.21 (0.07–0.56)
Other 0.83 (0.38–1.82)
Age 132.52 1 132.52 1.04 per year
(1.03–1.04)
0.000
Motor score of GCS 46.739 6a 7.790 0.000
No response 1 REFERENCE
Extending to pain 1.35 (0.64–2.87)
Abnormal flexion 1.6 (0.73–3.55)
Withdrawing to pain 0.58 (0.34–0.93)
Localizing to pain 0.57 (0.34–0.93)
Obeying commands 0.3 (0.18–0.48)
Not assessable 0.23 (0.09–0.61)
CT Marshall grade 59.238 5 11.856 0.000
6 1 REFERENCE
5 0.38 (0.22–0.67)
4 0.24 (0.03–1.8)
3 0.39 (0.19–0.78)
2 0.22 (0.13–0.38)
1 0.52 (0.27–0.84)
Traumatic SAH 10.149 1 10.149 0.001
Absent 1 REFERENCE
Present 1.57 (1.17–2.11)
Hypotension [blood
pressure< 90mmHg
within the first 24 hours]
4.002 1 4.4002 0.046
Absent 1 REFERENCE
Present 1.8 (1.2–2.7)
Hypoxia [PO2< 8kPa
or SaO2< 85%
in the first 24 hours]
0.945 1 0.945 0.331
No hypoxia 1 REFERENCE
Confirmed hypoxia 0.67 (0.3–1.5)
Pupillary reactivity 9.112 2 4.556 0.011
Both reacting 1 REFERENCE
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influence the outcome of TBI in the same cohort of
patients studied here.24
Although most mitochondrial proteins are encoded
by nuclear DNA, mtDNA encodes key components;
these include 13 key subunits of the electron transport
chain, as well as essential components of the translational
machinery (Fig 2). MtDNA haplogroup is a determinant
of the efficiency of oxidative phosphorylation
(OXPHOS), with substantial physiological and patho-
physiological implications. In crude terms, it is thought
that haplogroups conferring more or less efficient
OXPHOS may have evolved in response to selective pres-
sures of food scarcity and cold climate, respectively.25,26
The differential susceptibility to age-related neurodege-
nerative conditions demonstrated by different mtDNA
haplogroups can then be framed in terms of the
OXPHOS efficiency, and resulting rate of generation of
reactive oxygen species (ROS), associated with individual
haplogroups4,5,20 (see Fig 2). A similar argument has
been proposed to explain the over-representation of hap-
logroups K, J, U, and D in centenarians.6–9
TBI, across the entire spectrum of severity, imposes
a metabolic stress associated with reduced OXPHOS
capacity of neural tissue, and generation of ROS.27–29
Our results point to a protective effect of haplogroup K.
The enzymatic components of the mitochondrial electron
transport chain (ETC) encoded by haplogroup K are
reported to be less tightly coupled than corresponding
variants in other haplogroups, which reduces ROS pro-
duction as a byproduct of adenosine triphosphate (ATP)
synthesis.20 ROS are key mediators of secondary cell
damage after a neurological insult, including TBI29,30; it
is therefore unsurprising that a less tightly coupled ETC
may confer a cell survival advantage after injury. Recent
literature also suggests that downregulation of ATP syn-
thesis after TBI may be a neuroprotective mecha-
nism.31,32 This may also provide an explanation for a
less tightly coupled ETC conferring a neuroprotective
effect in the case of haplogroup K.
Genomic Variants of mtDNA Differentially
Mitigate the Effect of Aging on TBI Outcome
Aging causes a progressive loss of mitochondrial function
and a reduction in OXPHOS enzyme activities in human
tissues, including the brain.33 In addition, mitochondria
are also both the source and the target of ROS damage,
as mtDNA lacks protective histones and DNA repair
enzymes.34 With aging, cells accumulate a progressively
larger burden of mtDNA damage, which is preferentially,
clonally amplified within cells. The mitochondrial ener-
getic output therefore declines and ROS production
increases, as does the propensity for apoptosis, leading to
progressive cell loss and tissue function decline.
It is important to remember that age is a very strong
determinant of outcome after TBI, with most studies
showing a linear relationship between age and TBI mortal-
ity and disability after the 3rd decade of life.19 We there-
fore reasoned that mtDNA haplogroups might
differentially affect resilience to TBI with advancing age.
We found a strong mitigating effect of haplogroups K and
T on the effect of aging on TBI outcome. The observed
effect of haplogroup K is compatible with its reduced ROS
TABLE 3: Continued
Parameter Category Chi-Square df F OR (95% CI) p
Only 1 reacting 1.71 (1.05–2.78)
Neither reacting 1.83 (1.09–3.08)
ApoE genotype
[e4 vs e2 or e3]
0.507 1 0.507 0.476
e4 1 REFERENCE
e2/e3 0.82 (0.41–1.63)
Interaction between
mtDNA haplogroup and age
13.439 5 2.688 0.02
Interaction between mtDNA
haplogroup and APOE e4
21.35 5 4.27 0.001
Effects of predictors of the ordered regression analysis on the collapsed Glasgow Outcome Scale. Chi-quare, degrees of freedom
(df ), F statistics, odds ratio (OR), and significance are shown. OR< 1 favors better outcome. As mtDNA haplogroup is a polyno-
mial term, the ORs for this parameter indicate the odds of better outcome for carriers of each haplogroup compared to noncarriers
of the same haplogroup.
aIncludes the 6 possible motor scores and the category “not assessable.”
CI5 confidence interval; CT5 computed tomography; GCS5Glasgow Coma Scale; SAH5 subarachnoid hemorrhage.
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output compared to other haplogroups.20 The effect of
haplogroup T is less clear, but it is of note that, similarly
to haplogroup K, haplogroup T has been found to be
under-represented in neurodegenerative conditions.4,5 It is
somewhat surprising that we did not see a similar interac-
tion between age and mtDNA haplogroup J, given the
close genetic relationship between haplogroups J and T. Of
note, these haplogroups are distinguished by different var-
iants of nicotinamide adenine dinucleotide (NADH) dehy-
drogenase, another key enzyme of the respiratory chain.
Haplogroup K Interacts with APOE e4
We did not find an association between APOE genotype
and outcome in our cohort. This is consistent with the
findings of the original study from which our cohort was
derived,11 despite some methodological differences
between the 2 studies. However, we found a very strong
interaction between APOE e4 and mtDNA haplogroup K.
A similar interaction has been reported by Carrieri et al
for AD; this study found significant under-representation
of haplogroups K and U in e4 carriers and concluded that
these haplogroups might neutralize the harmful effect of
the APOE e4 allele.23 As illustrated by Figure 1B, in our
cohort there is a strong effect of haplogroup K on out-
come in patients who are APOE e4 positive. For those
who lack APOE e4, haplogroup K appears to have no
impact on outcome. The low ROS production associated
with haplogroup K might be expected to mitigate the low
efficiency of the antioxidant activity of APOE e4,35 and
this would seem to be an attractive possible mechanism of
interaction for further study.
The Role of Mitochondrial Genome in the
Pathophysiology of TBI
Few studies to date have examined the role of the mito-
chondrial genome in TBI pathophysiology. In a small
study, long-term survivors of TBI were shown to have a
lower prevalence of key mtDNA deletions than age-
matched controls, raising the possibility that free radical–
induced accumulation of mtDNA damage may selectively
influence the survival of mitochondria or their host.36 In
another recent study of 336 patients by Conley et al, mito-
chondrial single nucleotide polymorphisms (SNPs) were
found to be significantly associated with patient outcomes
1 year after injury37; only severe TBI patients managed
with external ventricular drainage were eligible for this
study, but the findings are nonetheless broadly compatible
with ours. For example, Conley et al found the A10398G
mitochondrial SNP, located within the NADH–ubiquinone
oxidoreductase subunit-3 (ND3) locus encoding part of
complex I, to be associated with TBI outcome; the
A10398 and 10398G alleles of this SNP were associated,
respectively, with slower and faster recovery. The A10398
allele is found in haplogroup H and appears to increase
the susceptibility to neurodegenerative and mental health
disorders,5 whereas the 10398G allele is associated with
haplogroups K and J, and is reported to exert a protective
effect from the risk of PD. It is important to bear in mind
that the modifying role of an mtDNA haplogroup on
injury response or disease risk is most probably due to the
synergistic action of a set of different polymorphisms rather
than to the effect of a single polymorphism. Haplogroups
J and K belong to widely diverging mitochondrial clades,38
FIGURE 1: Effect of mtDNA haplogroups on outcome in
relation to age (A) and APOE genotype (B). Panel A shows
the linear regression lines of each haplogroup on a scatter
plot of outcome versus age. Each circle represents a case.
Haplogroups K and T clearly have different slopes from the
other haplogroups, indicating that age, which is a strong
determinant of outcome in traumatic brain injury, has a
comparatively smaller effect in patients who possess these
haplogroups. Panel B illustrates the interaction between
mtDNA haplogroups and APOE genotype on outcome, illus-
trated by the 95% confidence interval of the collapsed Glas-
gow Outcome Scale (GOS) score (15dead or vegetative,
25 severe disability, 35moderate disability, 45good out-
come) by mtDNA haplogroups and APOE e4 possession.
ANNALS of Neurology
192 Volume 75, No. 2
which may explain the different results obtained for the 2
haplogroups in our cohort.
No effective neuroprotective drugs for TBI have
emerged to date. The limited ability to explain the vari-
ability in response to injury has resulted in challenges in
dealing with signal-to-noise ratio and consequent under-
powering of many previous studies. Our findings have
the potential to contribute to effective patient stratifica-
tion in clinical trials, and mtDNA genomics should be
included in future outcome prediction models, for exam-
ple those developed on the basis of forthcoming compar-
ative effectiveness research studies. Moreover, the
molecular mechanisms of cell damage following TBI are
still poorly understood; our findings shed further light
on the pivotal role of mitochondria in the pathophysiol-
ogy of TBI and advance our understanding of the molec-
ular mechanisms regulated by mitochondrial genome.
The interpretation must accept certain limitations of
the study. First, our cohort was drawn from neurosurgical
admission, and the findings may not be generalizable to
unselected admissions. However, the study included a large
number of patients who were not severely injured, and so
the bias is likely to be limited. Second, although the
follow-up rate was extremely high, data are incomplete in
some participants, and mitochondrial genotyping was not
successful on all samples, although there is no suggestion
that test failures did not occur randomly. Third, outcome
was assessed by GOS, which is a global measure of out-
come; the possible effects of mtDNA haplogroups on the
individual components of outcome (eg, neuropsychological
health status, behavior, social interaction, and functional
performance) would have added further dimensionality to
our findings, although a much larger study would have
been required to explore multiple parameters. Neverthe-
less, GOS remains the most widely used method of assess-
ment of outcome in TBI and has several advantages.
These include its applicability across all ranges of age,
severity, and outcome; the high reliability and validity of
assessment achieved by the structured approach used in
this study; and its high degree of correlation with the
results of specific assessments focused on limited aspects of
the state of survivors (eg, cognitive, behavioral, and emo-
tional sequelae) and of detailed multidimensional assess-
ments of health and psychosocial state, such as the SF-36
questionnaire.39 Finally, mitochondrial haplogroup fre-
quencies vary greatly between populations, and the nuclear
genetic background of subjects with haplogroups T and K
may differ from the nuclear genetic background of other
mtDNA haplogroups. Therefore, it is possible that further
associations of mtDNA haplogroups with particular
nuclear genotypes are responsible for our findings, rather
than the mtDNA haplogroups themselves. This issue is
FIGURE 2: The human mitochondrial DNA and known and putative genetic location of mutations associated with neurological
conditions. ATP5 adenosine triphosphate; MELAS5mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes;
MERRF5myoclonic epilepsy with ragged red fibers; MND5motor neuron disease; NADH5nicotinamide adenine dinucleotide;
TBI5 traumatic brain injury. Adapted from the Free Software Foundation and licensed under the GNU Free Documentation
License.
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likely to be minimized by the analysis being restricted to a
cohort from a regional unit in Scotland.
Although our cohort had a representative distribu-
tion of mtDNA haplogroups with respect to Northern
European populations, like all genetic studies, it would
be advisable to validate our findings in different geo-
graphical regions and populations.
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